Model-Informed Prescribing for Patients with Multimorbidity

Abstract

Model-informed prescribing integrates quantitative models of pharmacokinetics (PK), pharmacodynamics (PD), and disease progression to individualize drug therapy, particularly in patients with multimorbidity. The complexity of managing multiple coexisting conditions necessitates tailored approaches to optimize efficacy, minimize adverse effects, and reduce polypharmacy-related risks. This article reviews the epidemiology of multimorbidity, explores its pathophysiological underpinnings, discusses clinical features and diagnostic challenges, and presents evidence-based strategies for model-informed treatment. Recent advances in computational modeling, real-world data integration, and guideline-driven recommendations are highlighted, underscoring the clinical and practical implications for healthcare professionals.

Introduction

Multimorbidity, defined as the coexistence of two or more chronic conditions in an individual, has emerged as a predominant challenge in modern clinical practice. As global populations age and medical advances prolong life, the prevalence of patients with multiple interacting diseases continues to rise. Traditional prescribing paradigms, often focused on single-disease management, are insufficient to address the intricacies of multimorbidity, which include altered drug pharmacology, increased susceptibility to adverse drug reactions, and complex drug-disease and drug-drug interactions. Model-informed prescribing, which leverages quantitative modeling approaches to individualize therapy, represents a paradigm shift toward precision medicine in this context. This review synthesizes current evidence and practical guidance for employing model-informed strategies to optimize pharmacotherapy in patients with multimorbidity.

Epidemiology / Disease Burden

The global burden of multimorbidity is substantial and increasing. Epidemiological studies indicate that over 50% of adults aged 65 and older live with at least two chronic conditions, with higher prevalence in socioeconomically disadvantaged populations. Multimorbidity is associated with increased healthcare utilization, higher rates of hospitalization, polypharmacy, and elevated mortality. The economic impact is significant due to the need for complex care coordination, frequent monitoring, and management of adverse drug events. As the population ages, the burden of multimorbidity is projected to escalate, further straining healthcare systems worldwide and underscoring the need for model-informed approaches that can streamline and optimize therapeutic decision-making.

Pathophysiology

The pathophysiology of multimorbidity is multifaceted, often involving shared risk factors, genetic predispositions, and overlapping pathobiological mechanisms. Chronic inflammation, metabolic dysregulation, and immune senescence are among the common threads linking conditions such as diabetes, cardiovascular disease, chronic kidney disease, and neurodegenerative disorders. These overlapping processes not only drive disease progression but also modulate drug absorption, distribution, metabolism, and excretion (ADME). Model-informed approaches use mechanistic PK/PD models to simulate these dynamic processes, facilitating a deeper understanding of how multimorbidity alters drug response and informing individualized dosing regimens.

Risk Factors

Major risk factors for multimorbidity include advancing age, genetic predisposition, low socioeconomic status, unhealthy lifestyle behaviors (such as smoking, physical inactivity, and poor diet), and environmental exposures. Certain populations, including those with mental health disorders or chronic infections, are at heightened risk. Polypharmacy itself can be both a consequence and a driver of multimorbidity, as inappropriate medication use may precipitate additional conditions through adverse effects or drug interactions. Recognizing these risk factors is essential for targeted interventions and the development of predictive models that can identify individuals most likely to benefit from model-informed prescribing.

Clinical Features

Patients with multimorbidity often present with a complex constellation of symptoms arising from the interplay of multiple conditions and their treatments. Common clinical features include fatigue, pain, cognitive impairment, and functional decline. The presence of multiple diseases can obscure symptom attribution, complicate diagnosis, and increase the risk of diagnostic overshadowing. Furthermore, the cumulative burden of symptoms contributes to reduced quality of life, increased psychological distress, and poorer clinical outcomes. Model-informed approaches can integrate multi-dimensional clinical data to support differential diagnosis and inform therapeutic strategies that address the whole patient rather than isolated disease entities.

Diagnosis

Diagnosing multimorbidity requires a comprehensive, patient-centered assessment that encompasses detailed medical history, physical examination, and judicious use of laboratory and imaging studies. Standardized tools such as the Cumulative Illness Rating Scale (CIRS) and Charlson Comorbidity Index (CCI) can aid in quantifying disease burden. Model-based diagnostic algorithms utilize real-world data and machine learning to identify patterns indicative of multimorbidity, predict progression, and stratify patients by risk. Such models facilitate early intervention and enable clinicians to anticipate complications related to drug therapy, such as altered pharmacokinetics or increased vulnerability to adverse reactions.

Treatment & Management

Effective management of multimorbidity demands an individualized, holistic approach that balances the benefits and risks of pharmacological and non-pharmacological interventions. Model-informed prescribing utilizes PK/PD modeling, Bayesian forecasting, and therapeutic drug monitoring to optimize drug selection and dosing. These models account for patient-specific factors such as organ function, genetic polymorphisms, comorbid conditions, and concomitant medications. Multidisciplinary care teams, including pharmacists and clinical pharmacologists, play a critical role in medication reconciliation and deprescribing to minimize polypharmacy. Non-pharmacological strategies, such as lifestyle modification and disease self-management education, are essential adjuncts to pharmacotherapy.

Recent Advances / Emerging Therapies

Recent years have witnessed substantial progress in computational modeling, real-world data integration, and the application of artificial intelligence (AI) in model-informed prescribing. Physiologically based pharmacokinetic (PBPK) models, population PK/PD analyses, and machine learning algorithms enable the simulation of complex drug-disease interactions in patients with multimorbidity. Digital health technologies, such as electronic health records (EHRs) and clinical decision support systems (CDSS), facilitate the real-time application of these models in clinical practice. Emerging therapies, including targeted biologics and gene therapies, require precise dosing strategies that are well-suited to model-informed approaches. Ongoing research aims to validate and refine these models using prospective clinical data, with the goal of improving patient outcomes and reducing the burden of adverse drug events.

Guideline Recommendations

Leading clinical guidelines, including those from the National Institute for Health and Care Excellence (NICE) and the American Geriatrics Society (AGS), advocate for individualized care plans that prioritize patient preferences, functional status, and life expectancy in the context of multimorbidity. These guidelines emphasize the importance of regular medication review, avoidance of inappropriate polypharmacy, and shared decision-making. Incorporating model-informed prescribing into routine care is increasingly recommended, particularly for patients with high disease burden, multiple medications, or significant organ dysfunction. The integration of quantitative modeling into clinical guidelines is an evolving area, with consensus statements highlighting the need for ongoing education and multidisciplinary collaboration.

Conclusion

Model-informed prescribing represents a transformative advancement in the management of patients with multimorbidity. By leveraging quantitative models and real-world data, clinicians can individualize therapy, mitigate risks, and improve outcomes in this complex patient population. Continued research, clinical validation, and integration into practice guidelines are essential to fully realize the promise of model-informed approaches. As the prevalence and burden of multimorbidity grow, embracing these strategies will be critical to delivering high-quality, patient-centered care for the most vulnerable members of society.